Author:
Serfert Yvonne,Wedemeyer Heiner
Publisher
Springer Berlin Heidelberg
Reference28 articles.
1. Boerekamps A, van den Berk GE, Lauw FN, Leyten EM, van Kasteren ME, van Eeden A et al (2018) Declining hepatitis c virus (HCV) incidence in Dutch human immunodeficiency virus-positive men who have sex with men after unrestricted access to HCV therapy. Clin Infect Dis 66:1360–1365. https://doi.org/10.1093/cid/cix1007
2. Bundesministerium für Gesundheit (2016) Strategie zur Eindämmung von HIV, Hepatitis B und C und anderen sexuell übertragbaren Infektionen. https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/5_Publikationen/Praevention/Broschueren/Strategie_BIS_2030_HIV_HEP_STI.pdf. Zugegriffen im Januar 2020
3. Chhatwal J, He T, Hur C, Lopez-Olivo MA (2017) Direct-acting antiviral agents for patients with hepatitis C virus genotype 1 infection are cost-saving. Clin Gastroenterol Hepatol 15:827–837. https://doi.org/10.1016/j.cgh.2016.09.015
4. Christensen C, Buggisch P, Mauss S, Böker KHW, Schott E, Klinker H, Zimmermann T et al (2018) Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: still a concern in clinical practice? Addiction 113:868–882. https://doi.org/10.1111/add.14128
5. Cornberg M, Petersen J, Schober A, Mauss S, Böker KHW, Link R et al (2017) Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. Aliment Pharmacol Ther 45:688–700. https://doi.org/10.1111/apt.13925